Opendata, web and dolomites

Hyalcis

Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hyalcis project word cloud

Explore the words cloud of the Hyalcis project. It provides you a very rough idea of what is the project "Hyalcis" about.

benefits    local    intrapleural    medicinal    protection    extremely    resistant    months    reaching    designation    limiting    curative    malignant    confirmed    hyalcis    25    effectiveness    safety    preparation    solution    linked    pleura    recovery    successfully    australia    feasibility    prevention    200m    achievable    precisely    43    industry    qualified    cisplatin    cancer    efficiency    planning    districts    die    mesothelioma    animals    satisfactory    tests    form    film    worldwide    aggressive    asbestos    construction    plumestars    difficult    plan    medical    2016    toxicity    rare    years    diagnose    drug    registration    hydrophilic    feedback    tumor    epithelial    full    surfaces    innovative    combined    thin    situ    biodegradable    concentrations    agency    company    surgery    release    anticancer    industrialization    treat    prolonged    financial    recurrence    treatment    provider    residual    introduces    japan    people    north    market    proposing    sufficiently    disease    flexible    competitors    polymeric    orphan    mesothelial    adhering    opportunity    capture    business    entitles    america    pleural    obtaining   

Project "Hyalcis" data sheet

The following table provides information about the project.

Coordinator
PLUMESTARS SRL 

Organization address
address: STRADA INZANI 1
city: PARMA PR
postcode: 43124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.plumestars.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLUMESTARS SRL IT (PARMA PR) coordinator 50˙000.00

Map

 Project objective

Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYALCIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYALCIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More